Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38002   clinical trials with a EudraCT protocol, of which   6235   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-000818-11
    Sponsor's Protocol Code Number:M-41008-48
    National Competent Authority:Portugal - INFARMED
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2019-07-30
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedPortugal - INFARMED
    A.2EudraCT number2019-000818-11
    A.3Full title of the trial
    Clinical study to evaluate the efficacy and safety of a combination therapy with dimethyl fumarate (DMF) and NB-UVB phototherapy (versus DMF monotherapy) in adults with moderate-to-severe chronic plaque psoriasis (PHOTOSKILL)
    Estudo clínico para avaliar a eficácia e a segurança de uma terapêutica combinada com fumarato de dimetilo (DMF) e fototerapia com UVB de banda estreita (NB-UVB) (em comparação com monoterapia com DMF) em adultos com psoríase em placas crónica moderada a grave (PHOTOSKILL).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Clinical study to evaluate the efficacy and safety of a combination therapy with dimethyl fumarate (DMF) and NB-UVB phototherapy (versus DMF monotherapy) in adults with moderate-to-severe chronic plaque psoriasis (PHOTOSKILL)
    Estudo clínico para avaliar a eficácia e a segurança de uma terapêutica combinada com fumarato de dimetilo (DMF) e fototerapia com UVB de banda estreita (NB-UVB) (em comparação com monoterapia com DMF) em adultos com psoríase em placas crónica moderada a grave (PHOTOSKILL).
    A.3.2Name or abbreviated title of the trial where available
    PHOTOSKILL study
    A.4.1Sponsor's protocol code numberM-41008-48
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAlmirall, S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAlmirall, S.A.
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAlmirall, S.A.
    B.5.2Functional name of contact pointInternat. Clinical Trial Manager
    B.5.3 Address:
    B.5.3.1Street AddressRda. General Mitre, 151
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08022
    B.5.3.4CountrySpain
    B.5.4Telephone number+34932917403
    B.5.6E-mailsara.herrero@almirall.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Skilarence
    D.2.1.1.2Name of the Marketing Authorisation holderAlmirall, S.A.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSkilarence
    D.3.4Pharmaceutical form Gastro-resistant tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDIMETHYL FUMARATE
    D.3.9.1CAS number 624-49-7
    D.3.9.3Other descriptive nameDIMETHYL FUMARATE
    D.3.9.4EV Substance CodeSUB13608MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Skilarence
    D.2.1.1.2Name of the Marketing Authorisation holderAlmirall, S.A.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSkilarence
    D.3.4Pharmaceutical form Gastro-resistant tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDIMETHYL FUMARATE
    D.3.9.1CAS number 624-49-7
    D.3.9.3Other descriptive nameDIMETHYL FUMARATE
    D.3.9.4EV Substance CodeSUB13608MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number120
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Moderate to severe chronic plaque psoriasis
    E.1.1.1Medical condition in easily understood language
    Moderate to severe chronic plaque psoriasis
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10071117
    E.1.2Term Plaque psoriasis
    E.1.2System Organ Class 100000004858
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of a DMF/NB-UVB PT combination regimen and DMF treatment alone in patients with moderate-to-severe chronic plaque psoriasis, as assessed by PASI 75 or PASI ≤3.
    E.2.2Secondary objectives of the trial
    1. To assess the efficacy of a DMF/NB-UVB PT combination regimen and DMF treatment alone (as assessed by PASI, BSA, and PGA.
    2. To assess the time to achieve a clinically meaningful improvement (as assessed by PASI) of a DMF/ NB-UVB PT combination regimen and DMF treatment alone.
    3. To assess the efficacy of DMF/ NB-UVB PT combination regimen and DMF treatment alone according to patient-reported outcomes (PRO) (DLQI, Skindex-16, pruritus-VAS, and WPAI).
    4. To assess cost-effectiveness (as assessed by health resources utilisation [HRU] and EQ-5D) of a DMF/ NB-UVB PT combination regimen and DMF treatment alone.
    5. To assess the safety and tolerability of a DMF/ NB-UVB PT combination regimen and DMF treatment alone.
    6. To assess adherence rate and patient satisfaction of a DMF/ NB-UVB PT combination regimen and DMF treatment alone.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1- Ability to understand and comply with the requirements of the study and communicate with the Investigator, and written, signed and dated informed consent given before any study related activity is performed.
    2-Male or female must be at least 18 years of age at the time of Screening Visit.
    3-Patients diagnosed with chronic plaque psoriasis of at least 6 months prior to the Screening Visit, and stable active plaque-type psoriasis (defined as without clinically significant flares during the 12 weeks before randomisation).
    4-Patients with the severity of psoriasis at Screening and Baseline visits defined by PASI score >5.
    5-Candidates whose disease is eligible for systemic treatment and PT (i.e. with lesions in areas that can be irradiated) at the Screening Visit.
    6-Patients who are PT naïve or who have not had PT at least 6 months before the Screening Visit.
    7-General good health, or a stable medical condition not considered likely to interfere with the conduct of the clinical study, as determined by the Investigator based upon results of medical history, laboratory results (within normal or clinically acceptable range limits) and physical examination (no clinical significant abnormal findings). Investigators are encouraged to consult with the Sponsor if there are questions regarding the significance of any out of range values.
    8-Complete record of at least the last 12 months prior to the Screening Visit of anti-psoriatic previous topical, PT and non-biologic systemic treatments, if any.
    9-Unlikely to conceive, as indicated by at least one “yes” answer to the following questions
    -Patient is a male
    -Patient is a surgically sterilized female by hysterectomy or bilateral tubal ligation
    -Patient is a postmenopausal female ≥45 years of age with >1 year since last menses. If a patient is <45 years of age, or cessation of menses is more than 3 months and less than 1 year, follicle stimulating hormone must be documented as elevated into the postmenopausal range (>60 mIU/mL) at the Screening visit
    -Patient is a non-sterilized and pre-menopausal female using a highly effective medically accepted method of contraception, during the study period and for 30 days after the last dose of the study drug
    Explanatory note: Highly effective methods of birth control are defined as a method with less than 1% failure rate per year which include:
    combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation1 (oral, injectable, implantable2), intrauterine device, intrauterine hormone-releasing system 2, bilateral tubal occlusion 2, vasectomised partner 2,3, and sexual abstinence 4.
    1 Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of the contraception method.
    2 Contraception methods that are considered to have low user dependency (according to the CTFG recommendations on contraception and pregnancy testing).
    3 Vasectomised partner is a highly effective birth control method provided that partner is the sole sexual partner of the woman who is considered of childbearing potential study participant and that the vasectomised partner has received medical assessment of the surgical success.
    4 Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of the risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the subject.
    10-For female patients of child-bearing potential, a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit. Additionally, they must agree to have urine pregnancy tests while on study medication.
    11-Patients willing to keep sun exposure of the trunk and limbs to none or minimal, occasional and unintentional, and not to use tanning booths or other ultraviolet (UV) light sources for the duration of the trial.
    E.4Principal exclusion criteria
    1-Female patients who are currently pregnant, who intend to become pregnant during the course of the study, or who are breastfeeding, unwillingness/inability to use appropriate measures of contraception
    2- Patients with a diagnosis of flexural, guttate, erythrodermic or pustular psoriasis
    3- Patients with a diagnosis and/or signs/symptoms suggestive of active psoriatic arthritis
    4- Drug-induced psoriasis (i.e., a new onset or current exacerbation of psoriasis from beta-blockers, calcium channel blockers, or lithium)
    5-History or evidence of skin disease (atopic dermatitis, eczema) or conditions (scarring, open wounds) other than chronic plaque-type psoriasis that might interfere with the study conduct or evaluations, or which exposes the patient to unacceptable risk by study participation
    6-Patients with a haematological abnormality at the Screening Visit as follows: platelet count <100,000/mm3, white blood cells (WBC) count < 3,000 cells/ mm3, lymphocyte count < 1,000/μL, haemoglobin, haematocrit, or red blood cell count outside 30% of the upper or lower limits of normal
    for the laboratory.
    7-History or concurrent malignancy (excluding successfully treated basal cell carcinoma, squamous cell carcinoma of the skin in situ, squamous cell carcinoma with no evidence of recurrence within 5 years or carcinoma in situ of the cervix that has been adequately treated).
    8- Presence of severe photodamage, actinic keratosis and/or clinically/histologically atypical moles.
    9- Patients suffering from active significant gastrointestinal problems (ulcers, diarrhoea, etc.).
    10-Patients with severe renal impairment (creatinine clearance <30 mL/min, estimated glomerular filtration rate (eGFR) using CKD-EPI Creatinine Equation or significant proteinuria (3+ or higher)
    11-Patients with abnormal liver enzymes:
    -if an enzyme was >3x the upper limit of the normal range (ULN): aspartate amino transferase (AST or SGOT), alanine amino transferase (ALT or SGPT), gamma-glutamyl-transferase (GGT), alkaline phosphatase (ALP)
    - if bilirubin was >2x ULN, for the other liver enzymes >2x ULN was exclusionary
    12-Patients with active infectious disease
    13- Patients on systemic therapy
    14- Patients with concomitant treatment with immunomodulating or immunosuppressive medication, or systemic corticosteroids
    15- History of hypersensitivity or allergy to the study drugs or its excipients
    16- Patients with history or evidence/indication of current drug and/or alcohol abuse or dependence, according to the judgment of the Investigator
    17- Patients with HIV-positive status or any other immunosuppressive disease
    18-Patients who have had a live vaccination within 4 weeks prior to the Baseline Visit, or intend to have a live vaccination during the course of the study, or have participated in a vaccine clinical study within 12 weeks of randomization
    19-Patient who intend to use any concomitant medication not permitted by this study or who have not undergone the required washout period, prior to the Baseline Visit, for a particular prohibited medication:
    -Topical psoriasis treatment (e.g. topical corticosteroids, vitamin A analogues, vitamin D analogues, coal tar, anthracene derivatives, salicylic acid preparations): 2 weeks
    -PT (other than the study PT, e.g. Psoralen-UVA therapy, tanning salon or homeadministered UVB): 6 months
    -Conventional systemic anti-psoriatic drugs, excluding fumarate-based drugs and PT: 4 weeks
    -Any other immunosuppressive medication (e.g. cytostatics, etc.): 6 months
    20- Patients who are hypersensitive to ingredients of the study drugs
    21- Patients previous enrolled in this study or participating in any other drug investigational trial within the 30 days (or five half-lives whichever is longer) prior to enrollment.
    22- Concurrent systematic therapy
    23- Patients with photosensitivity: hypersensitivity to sunlight or UVB light of any type; history of Lupus, polymorphic light eruption (PMLE), or any disease known to be worsened by UV light exposure
    24- Patients that intake concomitant medications that are known to be able to induce photosensitivity
    25-Patients with previous exposure to fumarate-based drug or a biologic systemic treatment (e.g. tumour necrosis factor-alpha inhibitors, IL-17 inhibitors, IL-17R inhibitors, IL-12/23 p40 inhibitors, IL-23p19 inhibitors or experimental biological product)
    26- Patients who failed to respond, did not tolerate, had relevant side-effects or with contra-indication to NB-UVB in the past
    27- Patients who are not eligible for PT according to the Investigator (e.g. patients with severe involvement of the scalp and/or skin folds).
    28- Patients who do not have logistic availability to fulfil all the PT sessions required in the study
    29- Patients previously randomised in the current study
    30- Patient who is part of the study team at the research site
    31-Patient with any other serious or uncontrolled physical or mental dysfunction
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of patients achieving “PASI 75 response OR PASI ≤3” at 24 weeks of treatment
    E.5.1.1Timepoint(s) of evaluation of this end point
    week 24
    E.5.2Secondary end point(s)
    Efficacy endpoints
    -Proportion of patients achieving a PASI 75 response at 24 weeks of treatment.
    -Proportion of patients achieving an absolute PASI score of ≤3 at 24 weeks of treatment.
    -Proportion (and number) of patients achieving PASI 75, PASI 90 responses as well as absolute PASI score of ≤5, ≤3 and ≤1 all visits*.
    -Absolute PASI score and percentage change from baseline in the absolute PASI score at all visits*.
    -Proportion (and number) of patients with a PGA score of 0 or 1 (‘clear’ or ‘almost clear’) at all visits*.
    -Absolute PGA score and change from baseline in the absolute PGA score at each visit*.
    -Absolute BSA score and change from baseline in the absolute BSA score at each visit*.
    -Time to achieve the primary composite endpoint (PASI 75 response OR to PASI score ≤3)
    -Time to PASI 75 response.
    -Time to PASI score ≤ 3.
    -Absolute DLQI score and percentage change from baseline in the absolute DLQI score at all visits*.
    -Proportion of patients achieving a DLQI score of 0 or 1 at all visits*.
    -Absolute Skindex-16 score and change from baseline in the absolute Skindex-16 score at all visits*.
    -Absolute pruritus-VAS score and change from baseline in the absolute pruritus-VAS score at all visits*.
    -Absolute WPAI score and change from baseline in the absolute WPAI score at all visits*
    * When the data is collected
    -HRU related to psoriasis collected at Week 24:
    • Number of visits related to psoriasis (including unscheduled)
    • Treatments related to psoriasis (including dose, route, frequency, duration, onset date, end date, and reasons for onset and discontinuation
    • Number of hospitalisation/s related to psoriasis (if any, number of hospitalisations and length [days])
    • Number of unscheduled/emergency room visits to the general practitioner/dermatologist related to psoriasis (if any, number [days]
    • Diagnostic procedures related to psoriasis (clinical examination, laboratory controls, biopsy [if any], others)
    • Percentage of HRU related to adverse reactions (ARs) to psoriasis-treatments generating costs (i.e. concomitant treatments, etc.)
    - Quality Adjusted Life Year (QALY) for 24 weeks of treatment will be calculated using the EQ-5D score
    E.5.2.1Timepoint(s) of evaluation of this end point
    please see section E.5.2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Dimethyl Fumarate as monotherapy
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA21
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 130
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state49
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 150
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-08-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-11-25
    P. End of Trial
    P.End of Trial StatusOngoing
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA